dasatinib + ixabepilone

A combination regimen of the small‑molecule tyrosine kinase inhibitor **dasatinib** and the epothilone B analog microtubule‑stabilizing chemotherapeutic **ixabepilone**, investigated in early‑phase clinical trials for advanced solid tumors and metastatic breast cancer. Dasatinib inhibits BCR‑ABL and Src family kinases, potentially enhancing chemosensitivity and reducing invasion, while ixabepilone stabilizes microtubules to induce mitotic arrest and apoptosis. Preclinical and clinical data reported synergy and modest clinical activity; a Phase I trial identified tolerable doses with frequent treatment‑related toxicities, and established schedules for combination therapy in solid tumors and metastatic breast cancer settings.[1][5][4][9]

Other names

dasatinib and ixabepilone